Regulation of Energy Balance and Metabolism - Mechanisms Behind and Beyond Obesity and Weight Loss (BALANCE)

November 1, 2019 updated by: University of Eastern Finland
The study aims to investigate homeostatic and hedonic mechanisms regulating appetite, energy balance and metabolism in obesity and the effects of three distinct obesity treatments on these regulatory mechanisms.

Study Overview

Status

Completed

Detailed Description

Obesity is widely acknowledged health problem affecting millions of people globally. Enormous efforts have been made to solve the problem, but long-term results of the conventional weight loss and/or weight management strategies have been poor indicating still inadequate understanding of the problem. Surgical, rather than weight-centred lifestyle interventions, have proved to be the most effective tool available to treat obesity within individuals suitable for obesity surgery. Current surgical interventions are, however, suitable only for a small subset of obese individuals. In general, there is a need for development of new approaches and therapies that are safer and more individualized to each patient in the struggle against obesity and related disorders. To achieve these goals, research must focus to investigate and understand the complex homeostatic and hedonic regulation of eating behavior and energy balance in different physiological and pathological conditions.

This study aims to investigate homeostatic and hedonic mechanisms regulating energy balance and metabolism in obesity and the effects of three distinct obesity treatments on these regulatory mechanisms. The regulatory mechanisms are investigated at the level of metabolism, autonomic and central nervous systems as well as subjective, both implicit and explicit, experiences.

A total of 90 obese female volunteers (18-65 years, body mass index > 35 kg/m2), of which 30 females waiting for bariatric surgery (SURG), 30 females attending a dietary treatment program for obesity (DIET) and 30 females attending Health at Every Size (HAES) program, will participate in the study. The obesity treatment for SURG and DIET groups follows the principles of the Current Care Guidelines for Obesity (adults) and the treatment for the HAES group applies the strategies of the non-diet wellness-based HAES program. The treatment programs of the DIET and HAES groups include 8-10 weekly group sessions organized by authorised nutritionist.

The study includes also two four-hour visits at the research laboratory of the Institute of Public Health and Clinical Nutrition, University of Eastern Finland, the first visit organized before the participants attend any of the obesity treatments and the second visit 12 months later. During the laboratory visits psychophysiological signals (EEG, ANS, facial EMG and eye tracking) are monitored and blood samples taken throughout the experimental period. Participants will also perform two computer-based test sessions, the first one at baseline and the second before a snack meal. Two meals (breakfast and snack meal) are offered to the participants during the experiment in order to study the regulatory mechanisms of interest both at the homeostatic and hedonic states.

Study Type

Interventional

Enrollment (Actual)

50

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • body mass index >34 kg/m2
  • native finnish speaker
  • right-handed

Exclusion Criteria:

  • pregnancy or breast feeding
  • severe visual impairments, severe scalp skin lesions or intracranial bleeding during previous six months
  • severe neurological, psychiatric or cardiovascular disease
  • type 1 or 2 diabetes mellitus
  • use of weight loss medications or other treatments known to affect weight
  • heavy alcohol use
  • any other condition (medical or other) the principal investigator considers as an obstacle to participation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: SURG
subjects attending bariatric surgery
bariatric surgery according to Finnish Current Care Guidelines for Obesity in adults
Active Comparator: DIET
subjects attending dietary weight loss program
dietary weight loss program according to Finnish Current Care Guidelines for Obesity in adults
Active Comparator: HAES
subjects attending Health At Every Size weight management program
treatment is based on the previously published procedure (e.g. Bacon et al. 2002) and Health At Every Size trademark, consisting of body acceptance, eating behaviour, physical activity, nutrition, and social support

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Implicit associations
Time Frame: Change from baseline D-score at 1 year
D-score of Implicit Association Test
Change from baseline D-score at 1 year
Explicit ratings
Time Frame: Change from baseline visual analogue scale at 1 year
Ratings on visual analogue scales for wanting and liking of presented foods
Change from baseline visual analogue scale at 1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Event-related potentials
Time Frame: Change from baseline event-related potentials at 1 year
Event-related potentials measured by EEG
Change from baseline event-related potentials at 1 year
Glucose
Time Frame: Change from baseline glucose at 1 year
Plasma glucose, fasting, postprandial
Change from baseline glucose at 1 year
Insulin
Time Frame: Change from baseline insulin at 1 year
plasma insulin, fasting, postprandial
Change from baseline insulin at 1 year
Ghrelin
Time Frame: Change from baseline ghrelin at 1 year
plasma ghrelin, fasting, postprandial
Change from baseline ghrelin at 1 year
Leptin
Time Frame: Change from baseline leptin at 1 year
serum leptin, fasting
Change from baseline leptin at 1 year
Peptide YY
Time Frame: Change from baseline PYY at 1 year
plasma peptide YY, fasting, postprandial
Change from baseline PYY at 1 year
Endocannabinoids
Time Frame: Change from baseline endocannabinoids at 1 year
plasma endocannabinoids, fasting, postprandial
Change from baseline endocannabinoids at 1 year
Weight
Time Frame: Change from baseline weight at 1 year
body weight, fasting
Change from baseline weight at 1 year
Eating behaviour
Time Frame: Change from baseline eating behaviour at 1 year
self-reported questionnaires
Change from baseline eating behaviour at 1 year
Psychosocial characteristics
Time Frame: Change from baseline psychosocial characteristics at 1 year
self-reported questionnaires
Change from baseline psychosocial characteristics at 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Leila J Karhunen, PhD, University of Eastern Finland

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2016

Primary Completion (Actual)

April 1, 2019

Study Completion (Actual)

April 1, 2019

Study Registration Dates

First Submitted

December 19, 2016

First Submitted That Met QC Criteria

June 7, 2018

First Posted (Actual)

June 8, 2018

Study Record Updates

Last Update Posted (Actual)

November 5, 2019

Last Update Submitted That Met QC Criteria

November 1, 2019

Last Verified

November 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe